rTMS and Botulinum Toxin in Benign Essential Blepharospasm

Completed · Not applicable · Has a placebo group

Conditions studied: Benign Essential Blepharospasm

In brief

Benign essential blepharospasm (BEB) is a functionally disabling focal dystonia. Botulinum neurotoxin (BoNT) therapy is suboptimal in many BEB patients. Repetitious transcranial magnetic stimulation (rTMS) therapy is a promising noninvasive therapy and has shown positive benefits in BEB. rTMS therapy can be easily combined with BoNT injections to enhance the effects of BoNT in BEB.

Key facts

Study ID

NCT02370875

Run by

University of Florida

People needed

12

Starts

2015-02-01

Expected to finish

2017-11-01

Last updated by the study team

2023-09-15

Who can join

Age: 30 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• subjects diagnosed with blepharospasm or cranio-cervical dystonia who receive BoNT therapy at the Center for Movement Disorders will be approached. The investigators will enroll only those subjects who report experiencing positive benefits with BoNT but lasting about 10 weeks or less.

You may not qualify if…

• pregnancy
• active seizure disorder
• significant cognitive impairment
• exposure to neuroleptics
• presence of a metallic body such as pacemaker, implants, prosthesis, artificial limb or joint, shunt, metal rods and hearing aid.

Where it is running

• Center for Movement Disorders and Neurorestoration — Gainesville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.